Computational Guided Drug Repurposing for Targeting 2'-O-Ribose Methyltransferase of SARS-CoV-2

13 April 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The recent outbreak of pandemic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led the world towards global health emergency. Currently no proper medicine or effective treatment strategies are available, therefore repurposing may play an important role in overcoming the situation. The SARS-CoV-2 genome encodes for 2-O-methyltransferase (2’OMTase) which plays a key role in methylation of viral RNA for evading host immune system. In the present study, the protein sequence of 2’OMTase of SARS-CoV-2 was analysed and its structure was modeled by comparative modeling approach and validated. The modeled structure displayed the conserved characteristic fold of class I MTase family. The library of 3000 drugs was screened against the active site of 2’OMTase. The docking analysis displayed that the active site of 2’OMTase accommodates an array of drugs which includes alkaloids, antivirals, cardiac glycosides, anticancer, steroids and other drugs. The results suggested that these drugs may be used potential inhibitors for 2’OMTase for combating the SARS-CoV-2 infection.

Keywords

SARS-CoV-2
2-O-methyltransferase
Repurposing

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.